Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 14Gynecologic 6Tumor-Agnostic 5Lymphoid 5Thoracic 4Other hematologic neoplasm 4Genitourinary 4Sarcoma 2CNS 2Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 5

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × aflibercept × Tumor-Agnostic × Clear all
NCT00876044 2016-05-05

QUTIE

Sanofi

Phase 1 Completed
88 enrolled
Tumor-Agnostic

Neoplasms

NCT01930552 2015-01-07

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Sanofi

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00545246 2013-10-16

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Sanofi

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT01148615 2012-01-13

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Sanofi

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00479076 2011-01-26

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Sanofi

Phase 1 Completed
22 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡